Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia--do the effects really add up?
Different therapy strategies for coronary disease in conventionally untreatable patients have been developed, among them transmyocardial laser revascularization (TMLR) and the application of growth factors. The objective of our study was to determine whether a combined therapy of TMLR with a vascula...
Gespeichert in:
Veröffentlicht in: | European journal of cardio-thoracic surgery 2003-01, Vol.23 (1), p.74-80 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 80 |
---|---|
container_issue | 1 |
container_start_page | 74 |
container_title | European journal of cardio-thoracic surgery |
container_volume | 23 |
creator | Heilmann, Claudia A U Attmann, Tim von Samson, Patrick Göbel, Heike Marmé, Dieter Beyersdorf, Friedhelm Lutter, Georg |
description | Different therapy strategies for coronary disease in conventionally untreatable patients have been developed, among them transmyocardial laser revascularization (TMLR) and the application of growth factors. The objective of our study was to determine whether a combined therapy of TMLR with a vascular endothelial growth factor(121) (VEGF(121)) plasmid is able to stimulate the development of sufficient collateral circulation and hereby to preserve cardiac function.
A severe stenosis of the left anterior descending artery was created in healthy pigs. After 1 week, perfusion and regional contractility were assessed at baseline. Afterwards, the ischemic area was treated with TMLR (n=8), intramyocardial injection of naked plasmid DNA encoding VEGF(121) (n=7), or both (n=7). Control animals were left untreated (n=8). After 3 months, the animals were re-examined and underwent immunohistological analysis.
The number of capillaries increased only after injection of VEGF(121) plasmid alone compared to untreated ischemia and to the other therapy groups, whereas the number of arterioles was higher following TMLR treatment alone or in combination with VEGF(121) than it was in the case in untreated ischemic animals. However, only combined VEGF(121)+TLMR therapy resulted in an improvement in regional myocardial blood flow in comparison with 1 week ischemia, indicating the efficient development of collateral circulation. In contrast, better regional contractility compared to the 1-week baseline, as well as restoration of the pre-ischemic values, were achieved by both VEGF(121) and combined VEGF(121)+TLMR therapies.
This study of chronic myocardial ischemia with a porcine model indicates a synergistic action of TMLR and VEGF(121) gene therapy. Combined treatment alone achieved an increase of regional myocardial perfusion, which accompanied arteriogenesis and corresponded with the restoration of regional function. |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72885836</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72885836</sourcerecordid><originalsourceid>FETCH-LOGICAL-p548-162a411b2006335fe6698131924ad85afd247ba8798a505c113aeec295acaf83</originalsourceid><addsrcrecordid>eNpNkM9Kw0AQxnNQbK2-guxJ9BDY3fzbnERKrULBg8VrmOxOmpVNNu4mlvhYPqEptuBpBr7fzHzfnAVzRhkNszyms-DS-w9KaRrx7CKYMR7nUULFPPjZOmh9M1oJTmkwxIBHRxx-gZeDAae_ode2JdI2pW5Rkb3ua3JSCbbK9jWaw-jO2f2kVSB76wjjjNy9r9ZPU3NPdtgimUAH3UiqSZa1s62W5N9p7WWNjYYwVPbAEqwqlL2f3IAxIwGlyNA9XAXnFRiP18e6CN6eVtvlc7h5Xb8sHzdhl8QiZCmHmLGSH0JHSYVpmgsWsZzHoEQCleJxVoLIcgEJTSRjESBKnicgoRLRIrj929o5-zmg74tm8ofGQIt28EXGhUhElE7gzREcygZV0TndgBuL04-jX3Ytebo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72885836</pqid></control><display><type>article</type><title>Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia--do the effects really add up?</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Heilmann, Claudia A U ; Attmann, Tim ; von Samson, Patrick ; Göbel, Heike ; Marmé, Dieter ; Beyersdorf, Friedhelm ; Lutter, Georg</creator><creatorcontrib>Heilmann, Claudia A U ; Attmann, Tim ; von Samson, Patrick ; Göbel, Heike ; Marmé, Dieter ; Beyersdorf, Friedhelm ; Lutter, Georg</creatorcontrib><description>Different therapy strategies for coronary disease in conventionally untreatable patients have been developed, among them transmyocardial laser revascularization (TMLR) and the application of growth factors. The objective of our study was to determine whether a combined therapy of TMLR with a vascular endothelial growth factor(121) (VEGF(121)) plasmid is able to stimulate the development of sufficient collateral circulation and hereby to preserve cardiac function.
A severe stenosis of the left anterior descending artery was created in healthy pigs. After 1 week, perfusion and regional contractility were assessed at baseline. Afterwards, the ischemic area was treated with TMLR (n=8), intramyocardial injection of naked plasmid DNA encoding VEGF(121) (n=7), or both (n=7). Control animals were left untreated (n=8). After 3 months, the animals were re-examined and underwent immunohistological analysis.
The number of capillaries increased only after injection of VEGF(121) plasmid alone compared to untreated ischemia and to the other therapy groups, whereas the number of arterioles was higher following TMLR treatment alone or in combination with VEGF(121) than it was in the case in untreated ischemic animals. However, only combined VEGF(121)+TLMR therapy resulted in an improvement in regional myocardial blood flow in comparison with 1 week ischemia, indicating the efficient development of collateral circulation. In contrast, better regional contractility compared to the 1-week baseline, as well as restoration of the pre-ischemic values, were achieved by both VEGF(121) and combined VEGF(121)+TLMR therapies.
This study of chronic myocardial ischemia with a porcine model indicates a synergistic action of TMLR and VEGF(121) gene therapy. Combined treatment alone achieved an increase of regional myocardial perfusion, which accompanied arteriogenesis and corresponded with the restoration of regional function.</description><identifier>ISSN: 1010-7940</identifier><identifier>PMID: 12493508</identifier><language>eng</language><publisher>Germany</publisher><subject>Animals ; Chronic Disease ; Collateral Circulation ; Combined Modality Therapy ; DNA - administration & dosage ; Endothelial Growth Factors - administration & dosage ; Endothelial Growth Factors - genetics ; Genetic Therapy - methods ; Injections ; Intercellular Signaling Peptides and Proteins - administration & dosage ; Intercellular Signaling Peptides and Proteins - genetics ; Laser Therapy - methods ; Lymphokines - administration & dosage ; Lymphokines - genetics ; Myocardial Ischemia - surgery ; Myocardial Ischemia - therapy ; Myocardial Revascularization - methods ; Neovascularization, Physiologic ; Swine ; Transfection - methods ; Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors</subject><ispartof>European journal of cardio-thoracic surgery, 2003-01, Vol.23 (1), p.74-80</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12493508$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Heilmann, Claudia A U</creatorcontrib><creatorcontrib>Attmann, Tim</creatorcontrib><creatorcontrib>von Samson, Patrick</creatorcontrib><creatorcontrib>Göbel, Heike</creatorcontrib><creatorcontrib>Marmé, Dieter</creatorcontrib><creatorcontrib>Beyersdorf, Friedhelm</creatorcontrib><creatorcontrib>Lutter, Georg</creatorcontrib><title>Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia--do the effects really add up?</title><title>European journal of cardio-thoracic surgery</title><addtitle>Eur J Cardiothorac Surg</addtitle><description>Different therapy strategies for coronary disease in conventionally untreatable patients have been developed, among them transmyocardial laser revascularization (TMLR) and the application of growth factors. The objective of our study was to determine whether a combined therapy of TMLR with a vascular endothelial growth factor(121) (VEGF(121)) plasmid is able to stimulate the development of sufficient collateral circulation and hereby to preserve cardiac function.
A severe stenosis of the left anterior descending artery was created in healthy pigs. After 1 week, perfusion and regional contractility were assessed at baseline. Afterwards, the ischemic area was treated with TMLR (n=8), intramyocardial injection of naked plasmid DNA encoding VEGF(121) (n=7), or both (n=7). Control animals were left untreated (n=8). After 3 months, the animals were re-examined and underwent immunohistological analysis.
The number of capillaries increased only after injection of VEGF(121) plasmid alone compared to untreated ischemia and to the other therapy groups, whereas the number of arterioles was higher following TMLR treatment alone or in combination with VEGF(121) than it was in the case in untreated ischemic animals. However, only combined VEGF(121)+TLMR therapy resulted in an improvement in regional myocardial blood flow in comparison with 1 week ischemia, indicating the efficient development of collateral circulation. In contrast, better regional contractility compared to the 1-week baseline, as well as restoration of the pre-ischemic values, were achieved by both VEGF(121) and combined VEGF(121)+TLMR therapies.
This study of chronic myocardial ischemia with a porcine model indicates a synergistic action of TMLR and VEGF(121) gene therapy. Combined treatment alone achieved an increase of regional myocardial perfusion, which accompanied arteriogenesis and corresponded with the restoration of regional function.</description><subject>Animals</subject><subject>Chronic Disease</subject><subject>Collateral Circulation</subject><subject>Combined Modality Therapy</subject><subject>DNA - administration & dosage</subject><subject>Endothelial Growth Factors - administration & dosage</subject><subject>Endothelial Growth Factors - genetics</subject><subject>Genetic Therapy - methods</subject><subject>Injections</subject><subject>Intercellular Signaling Peptides and Proteins - administration & dosage</subject><subject>Intercellular Signaling Peptides and Proteins - genetics</subject><subject>Laser Therapy - methods</subject><subject>Lymphokines - administration & dosage</subject><subject>Lymphokines - genetics</subject><subject>Myocardial Ischemia - surgery</subject><subject>Myocardial Ischemia - therapy</subject><subject>Myocardial Revascularization - methods</subject><subject>Neovascularization, Physiologic</subject><subject>Swine</subject><subject>Transfection - methods</subject><subject>Vascular Endothelial Growth Factor A</subject><subject>Vascular Endothelial Growth Factors</subject><issn>1010-7940</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkM9Kw0AQxnNQbK2-guxJ9BDY3fzbnERKrULBg8VrmOxOmpVNNu4mlvhYPqEptuBpBr7fzHzfnAVzRhkNszyms-DS-w9KaRrx7CKYMR7nUULFPPjZOmh9M1oJTmkwxIBHRxx-gZeDAae_ode2JdI2pW5Rkb3ua3JSCbbK9jWaw-jO2f2kVSB76wjjjNy9r9ZPU3NPdtgimUAH3UiqSZa1s62W5N9p7WWNjYYwVPbAEqwqlL2f3IAxIwGlyNA9XAXnFRiP18e6CN6eVtvlc7h5Xb8sHzdhl8QiZCmHmLGSH0JHSYVpmgsWsZzHoEQCleJxVoLIcgEJTSRjESBKnicgoRLRIrj929o5-zmg74tm8ofGQIt28EXGhUhElE7gzREcygZV0TndgBuL04-jX3Ytebo</recordid><startdate>200301</startdate><enddate>200301</enddate><creator>Heilmann, Claudia A U</creator><creator>Attmann, Tim</creator><creator>von Samson, Patrick</creator><creator>Göbel, Heike</creator><creator>Marmé, Dieter</creator><creator>Beyersdorf, Friedhelm</creator><creator>Lutter, Georg</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200301</creationdate><title>Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia--do the effects really add up?</title><author>Heilmann, Claudia A U ; Attmann, Tim ; von Samson, Patrick ; Göbel, Heike ; Marmé, Dieter ; Beyersdorf, Friedhelm ; Lutter, Georg</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p548-162a411b2006335fe6698131924ad85afd247ba8798a505c113aeec295acaf83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>Chronic Disease</topic><topic>Collateral Circulation</topic><topic>Combined Modality Therapy</topic><topic>DNA - administration & dosage</topic><topic>Endothelial Growth Factors - administration & dosage</topic><topic>Endothelial Growth Factors - genetics</topic><topic>Genetic Therapy - methods</topic><topic>Injections</topic><topic>Intercellular Signaling Peptides and Proteins - administration & dosage</topic><topic>Intercellular Signaling Peptides and Proteins - genetics</topic><topic>Laser Therapy - methods</topic><topic>Lymphokines - administration & dosage</topic><topic>Lymphokines - genetics</topic><topic>Myocardial Ischemia - surgery</topic><topic>Myocardial Ischemia - therapy</topic><topic>Myocardial Revascularization - methods</topic><topic>Neovascularization, Physiologic</topic><topic>Swine</topic><topic>Transfection - methods</topic><topic>Vascular Endothelial Growth Factor A</topic><topic>Vascular Endothelial Growth Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Heilmann, Claudia A U</creatorcontrib><creatorcontrib>Attmann, Tim</creatorcontrib><creatorcontrib>von Samson, Patrick</creatorcontrib><creatorcontrib>Göbel, Heike</creatorcontrib><creatorcontrib>Marmé, Dieter</creatorcontrib><creatorcontrib>Beyersdorf, Friedhelm</creatorcontrib><creatorcontrib>Lutter, Georg</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cardio-thoracic surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Heilmann, Claudia A U</au><au>Attmann, Tim</au><au>von Samson, Patrick</au><au>Göbel, Heike</au><au>Marmé, Dieter</au><au>Beyersdorf, Friedhelm</au><au>Lutter, Georg</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia--do the effects really add up?</atitle><jtitle>European journal of cardio-thoracic surgery</jtitle><addtitle>Eur J Cardiothorac Surg</addtitle><date>2003-01</date><risdate>2003</risdate><volume>23</volume><issue>1</issue><spage>74</spage><epage>80</epage><pages>74-80</pages><issn>1010-7940</issn><abstract>Different therapy strategies for coronary disease in conventionally untreatable patients have been developed, among them transmyocardial laser revascularization (TMLR) and the application of growth factors. The objective of our study was to determine whether a combined therapy of TMLR with a vascular endothelial growth factor(121) (VEGF(121)) plasmid is able to stimulate the development of sufficient collateral circulation and hereby to preserve cardiac function.
A severe stenosis of the left anterior descending artery was created in healthy pigs. After 1 week, perfusion and regional contractility were assessed at baseline. Afterwards, the ischemic area was treated with TMLR (n=8), intramyocardial injection of naked plasmid DNA encoding VEGF(121) (n=7), or both (n=7). Control animals were left untreated (n=8). After 3 months, the animals were re-examined and underwent immunohistological analysis.
The number of capillaries increased only after injection of VEGF(121) plasmid alone compared to untreated ischemia and to the other therapy groups, whereas the number of arterioles was higher following TMLR treatment alone or in combination with VEGF(121) than it was in the case in untreated ischemic animals. However, only combined VEGF(121)+TLMR therapy resulted in an improvement in regional myocardial blood flow in comparison with 1 week ischemia, indicating the efficient development of collateral circulation. In contrast, better regional contractility compared to the 1-week baseline, as well as restoration of the pre-ischemic values, were achieved by both VEGF(121) and combined VEGF(121)+TLMR therapies.
This study of chronic myocardial ischemia with a porcine model indicates a synergistic action of TMLR and VEGF(121) gene therapy. Combined treatment alone achieved an increase of regional myocardial perfusion, which accompanied arteriogenesis and corresponded with the restoration of regional function.</abstract><cop>Germany</cop><pmid>12493508</pmid><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1010-7940 |
ispartof | European journal of cardio-thoracic surgery, 2003-01, Vol.23 (1), p.74-80 |
issn | 1010-7940 |
language | eng |
recordid | cdi_proquest_miscellaneous_72885836 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current) |
subjects | Animals Chronic Disease Collateral Circulation Combined Modality Therapy DNA - administration & dosage Endothelial Growth Factors - administration & dosage Endothelial Growth Factors - genetics Genetic Therapy - methods Injections Intercellular Signaling Peptides and Proteins - administration & dosage Intercellular Signaling Peptides and Proteins - genetics Laser Therapy - methods Lymphokines - administration & dosage Lymphokines - genetics Myocardial Ischemia - surgery Myocardial Ischemia - therapy Myocardial Revascularization - methods Neovascularization, Physiologic Swine Transfection - methods Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors |
title | Transmyocardial laser revascularization combined with vascular endothelial growth factor 121 (VEGF121) gene therapy for chronic myocardial ischemia--do the effects really add up? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T11%3A23%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transmyocardial%20laser%20revascularization%20combined%20with%20vascular%20endothelial%20growth%20factor%20121%20(VEGF121)%20gene%20therapy%20for%20chronic%20myocardial%20ischemia--do%20the%20effects%20really%20add%20up?&rft.jtitle=European%20journal%20of%20cardio-thoracic%20surgery&rft.au=Heilmann,%20Claudia%20A%20U&rft.date=2003-01&rft.volume=23&rft.issue=1&rft.spage=74&rft.epage=80&rft.pages=74-80&rft.issn=1010-7940&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E72885836%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72885836&rft_id=info:pmid/12493508&rfr_iscdi=true |